iTeos Therapeutics
Rue des Frères Wright 29
Gosselies
6041
Website: http://www.iteostherapeutics.com
Email: info@iteostherapeutics.com
About iTeos Therapeutics
iTeos was founded in 2011 as a spin off of the Ludwig Cancer Research (LICR) and de Duve Institute at University of Louvain (UCL). iTeos started its operation in 2012 by building its research insights based upon the unparalleled expertise of the LICR, a world-class Research Institute in the fields of tumor immunology, therapeutic cancer vaccines, cancer biology and translational medicine in cancer.YEAR FOUNDED:
2011
LEADERSHIP:
Founder and CEO: Michel Detheux
CSO: Christophe Queva
CMO: Alain Thibault
CFO: Yves Mertens
JOBS:
Please click here for iTeos job opportunities.
CLINICAL TRIAL:
Please click here for clinical trial information.
71 articles about iTeos Therapeutics
-
iTeos Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
3/6/2024
iTeos Therapeutics, Inc. reported financial results for the fourth quarter and full year ended December 31, 2023 and provided a business update.
-
iTeos Appoints Oncology Veteran Jill DeSimone to Its Board of Directors
3/6/2024
iTeos Therapeutics, Inc. announced the appointment of Jill DeSimone to its Board of Directors, effective March 7, 2024, where she will serve on the Company’s audit committee.
-
iTeos to Highlight Preclinical Data on First-In-Class EOS-984 Targeting ENT1 at the American Association for Cancer Research Annual Meeting 2024
3/5/2024
iTeos Therapeutics, Inc. announced a poster presentation of preclinical data on EOS-984, a first-in-class small molecule antagonist targeting equilibrative nucleoside transporter 1, at the American Association for Cancer Research Annual Meeting, being held April 5-10, 2024 in San Diego, California.
-
iTeos to Participate in Upcoming March 2024 Investor Conferences
3/1/2024
iTeos Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, announced that company management will participate in two upcoming investor conferences in March.
-
iTeos Announces 2024 Strategic Priorities and Anticipated Milestones
1/8/2024
iTeos Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, outlined business updates and strategic priorities for 2024.
-
iTeos to Present at the 42nd Annual J.P. Morgan Healthcare Conference
1/3/2024
iTeos Therapeutics, Inc. announced that Michel Detheux, Ph.D., President and Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference being held in San Francisco, CA on Wednesday, January 10, 2024 at 3:00 p.m. PST.
-
iTeos to Present at the Piper Sandler 35th Annual Healthcare Conference
11/21/2023
iTeos Therapeutics, Inc. today announced that management will participate in a fireside chat at the upcoming Piper Sandler 35th Annual Healthcare Conference in New York City on Tuesday, November 28, 2023 at 1:30 p.m. ET.
-
iTeos Reports Third Quarter 2023 Financial Results and Provides Business Updates
11/7/2023
iTeos Therapeutics, Inc. reported financial results for the third quarter ended September 30, 2023 and provided a business update.
-
iTeos Reports Second Quarter 2023 Financial Results and Provides Business Updates
8/8/2023
iTeos Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, reported financial results for the second quarter ended June 30, 2023 and provided a business update.
-
iTeos Reports First Quarter 2023 Financial Results and Provides Business Updates
5/10/2023
iTeos Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2023 and provided business updates on belrestotug, its anti-TIGIT antibody; inupadenant, its adenosine A2A receptor antagonist; and EOS-984, a first-in-class small molecule program targeting a novel mechanism in the adenosine pathway.
-
iTeos Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
3/15/2023
iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today reported financial results for the fourth quarter and full year ended December 31, 2022.
-
iTeos to Present at SVB Securities Global Biopharma Conference
2/7/2023
iTeos Therapeutics, Inc. today announced that Michel Detheux, Ph.D., President and Chief Executive Officer, will present at the SVB Securities Global Biopharma Conference being held virtually on Tuesday, February 14, 2023 at 10:00 a.m. EST.
-
iTeos Provides Business Updates and Clinical Development Plans for 2023
1/9/2023
iTeos Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, outlined business updates that are anticipated to advance its position in 2023, building a path to registration for its promising immunotherapy portfolio.
-
iTeos to Present at the 41st Annual J.P. Morgan Healthcare Conference
1/3/2023
iTeos Therapeutics, Inc. announced that Michel Detheux, Ph.D., President and Chief Executive Officer, will present at the 41st Annual J.P. Morgan Conference being held in San Francisco, CA on Tuesday, January 10, 2023 at 8:15 a.m. PST.
-
iTeos to Present at the Piper Sandler 34th Annual Healthcare Conference
11/22/2022
iTeos Therapeutics, Inc. today announced that Michel Detheux, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the upcoming Piper Sandler 34th Annual Healthcare Conference in New York City on Tuesday, November 29, 2022.
-
iTeos Reports Third Quarter 2022 Financial Results and Provides Business Updates
11/10/2022
iTeos Therapeutics, Inc. reported financial results for the third quarter ended September 30, 2022 and provided corporate highlights.
-
iTeos Reports Second Quarter 2022 Financial Results and Provides Business Update
8/10/2022
iTeos Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, reported financial results for the second quarter ended June 30, 2022 and provided corporate highlights.
-
iTeos to Present at the 2022 Wedbush PacGrow Healthcare Conference
8/2/2022
iTeos Therapeutics, Inc. announced that Michel Detheux, PhD, President and Chief Executive Officer, will participate in a panel discussion at the upcoming 2022 Wedbush PacGrow Healthcare Conference titled: “IOs Wide Open – Opportunities and Challenges in Immuno-Oncology” on Tuesday, August 9, 2022 at 8:00 a.m.
-
Genentech's flop of its anti-TIGIT drug has cast a shadow of doubt over the numerous companies in the process of developing their own anti-TIGIT drugs.
-
iTeos Reports First Quarter 2022 Financial Results and Provides Business Update
5/12/2022
iTeos Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2022 and provided recent corporate highlights.